# A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC

Source: https://onco.cc/trials/nct05054439/  
OnCo record `nct05054439` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SI-B001, Paclitaxel / nab-paclitaxel, Docetaxel in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC is a phase 2 interventional study registered as NCT05054439 by Sichuan Baili Pharmaceutical Co., Ltd., with 45 participants enrolled, started 2021-12-22 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B001, Paclitaxel, docetaxel. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05054439
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT05054439: https://clinicaltrials.gov/study/NCT05054439

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [SI-B001](https://onco.cc/drugs/si-b001/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05054439.json